Outpatient parenteral antimicrobial therapy in the time of COVID-19: The urgent need for better insurance coverage

Research output: Contribution to journalReview articlepeer-review

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19), are placing unprecedented pressure on every health care system. Patients who require weeks of intravenous antibiotic therapy after hospital discharge due to severe bacterial infections, generally referred to as outpatient parenteral antibiotic therapy (OPAT), are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the health care system. To reduce the risk of COVID-19 among this vulnerable patient population, providers overseeing OPAT care need to consider the relative safety of the different OPAT sites of care. Home-based OPAT should be emphasized to minimize hospital stays and prevent skilled nursing facility admissions. Medicare reimbursement policies need to urgently change to provide comprehensive coverage of home infusion services.

Original languageEnglish (US)
Article numberofaa287
JournalOpen Forum Infectious Diseases
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2020

Keywords

  • Coronavirus
  • Home infusion
  • Infection prevention
  • Nursing homes
  • Pandemic

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Outpatient parenteral antimicrobial therapy in the time of COVID-19: The urgent need for better insurance coverage'. Together they form a unique fingerprint.

Cite this